Literature DB >> 32588926

Pembrolizumab Improves Progression-Free Survival in Relapsed/Refractory Hodgkin Lymphoma.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32588926      PMCID: PMC7330920          DOI: 10.1634/theoncologist.2020-0561

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  2 in total

1.  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Authors:  Joseph M Connors; Wojciech Jurczak; David J Straus; Stephen M Ansell; Won S Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L Zinzani; David Cunningham; Andras Rosta; Neil C Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A Jolin; Dirk Huebner; John Radford
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

2.  Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.

Authors:  Robert Chen; Pier Luigi Zinzani; Hun Ju Lee; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Jianxin Lin; Eunhee Kim; Akash Nahar; Arun Balakumaran; Craig H Moskowitz
Journal:  Blood       Date:  2019-08-13       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.